Patients want a better, easier option for migraine care.
So do we.
Relaspen is being developed to put the power of a better, faster migraine treatment, with no harsh side effects, into the hands of the patients who need it. Relaspen is being developed as a self-administered intra-nasal treatment that delivers a local anesthetic directly to the SPG (Sphenopalatine Ganglion) nerve, located in the posterior nasal cavity. By blocking, or “relaxing” this nerve, patients can stop an acute migraine anytime, anywhere, in as little as 15 minutes.
How Relaspen is Different
Relaspen is the first medical device designed to allow patients to easily and safely self-administer an SPG block to treat an acute migraine. There are three other SPG block catheter devices currently FDA cleared and available on the market, but none of them are designed for patient self-administration. Currently, the SPG block procedure is only performed in physician offices and hospitals. Relaspen aims to allow patients to have access to this revolutionary migraine treatment with the push of a button.
What’s Next for Relaspen
Relaspen is being developed by Migraine Solutions, LLC, and is currently patent pending. Our pathway to market entails product research and development to maximize efficacy and ease of use, followed by clinical trials and submission for FDA approval.
We are currently in the prototype phase. Interested in learning more or partnering with us? Contact us at email@example.com.
Migraine is the 6th most disabling disease in the world, according to the WHO. There are 39 million migraine sufferers in the US and 1 billion worldwide. Despite the wide array of treatment possibilities, less than one third of migraine sufferers report being satisfied with their current headache treatment.